ProCE Banner Activity

CE / CME

Evolving Treatment Strategies for CLL/SLL and MCL

PCE On Demand Live Presentation

Treatment options for B-cell malignancies including chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and mantle cell lymphoma (MCL) are rapidly changing with the addition of Bruton's tyrosine kinase (BTK) inhibitors ibrutinib, acalabrutinib, and zanubrutinib, as well as the BCL2 inhibitor venetoclax. This activity provides expert advice on how to select preferred treatment regimens for your patients with CLL/SLL and MCL, as well as manage treatment-related adverse events to provide optimal care.

Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits

Released: August 15, 2022

Expiration: August 14, 2023

No longer available for credit.

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

Acknowledgement

This activity is supported by an educational grant from: AstraZeneca.

Provided by

ProCE Banner

Supporters

AstraZeneca

Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess recent clinical trial data for new and emerging therapies for CLL/SLL and MCL

  • Construct individualized treatment plans for CLL/SLL and MCL using novel therapies

  • Identify adverse events associated with new therapies for CLL/SLL and MCL in order to appropriately manage them

Disclosure

All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Beth Sandy, MSN, CRNP: consultant/advisor/speaker: Amgen, AstraZeneca, Janssen, Jazz, Merck, Takeda.

Beth Faiman, PhD, MSN, APRN-BC, AOCH, has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Beth Sandy, MSN, CRNP, as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: August 15, 2022
Expiration date: August 14, 2023

Format

On-demand webcast

Disclaimer

The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.

Accreditation

PCE

Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP Course Advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania

Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.

Additional Information

Program Medium

This program has been made available online.